User login
Key clinical point: Vitamin D deficiency in patients with psoriatic arthritis (PsA) had worse impact on the retention rate of the first biological disease-modifying antirheumatic drug (bDMARD) and response to methotrexate and was associated with severe disease course in terms of sacroiliitis.
Major finding: The risk for discontinuation of the first bDMARD (hazard ratio [HR] 2.129; P = .011) and methotrexate discontinuation because of therapy failure (HR 2.168; P = .002) were significantly higher among patients with 25(OH)D level of ≤20 vs 20-30 and ≥30 ng/mL, with the prevalence of sacroiliitis being significantly higher in patients with 25(OH)D level of ≤20 vs ≥30 ng/mL (P = .0001).
Study details: Findings are from a retrospective study including 233 patients with PsA.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Rotondo C et al. Vitamin D status and psoriatic arthritis: Association with the risk for sacroiliitis and influence on the retention rate of methotrexate monotherapy and first biological drug survival—A retrospective study. Int J Mol Sci. 2023;24(6):5368 (Mar 10). Doi: 10.3390/ijms24065368
Key clinical point: Vitamin D deficiency in patients with psoriatic arthritis (PsA) had worse impact on the retention rate of the first biological disease-modifying antirheumatic drug (bDMARD) and response to methotrexate and was associated with severe disease course in terms of sacroiliitis.
Major finding: The risk for discontinuation of the first bDMARD (hazard ratio [HR] 2.129; P = .011) and methotrexate discontinuation because of therapy failure (HR 2.168; P = .002) were significantly higher among patients with 25(OH)D level of ≤20 vs 20-30 and ≥30 ng/mL, with the prevalence of sacroiliitis being significantly higher in patients with 25(OH)D level of ≤20 vs ≥30 ng/mL (P = .0001).
Study details: Findings are from a retrospective study including 233 patients with PsA.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Rotondo C et al. Vitamin D status and psoriatic arthritis: Association with the risk for sacroiliitis and influence on the retention rate of methotrexate monotherapy and first biological drug survival—A retrospective study. Int J Mol Sci. 2023;24(6):5368 (Mar 10). Doi: 10.3390/ijms24065368
Key clinical point: Vitamin D deficiency in patients with psoriatic arthritis (PsA) had worse impact on the retention rate of the first biological disease-modifying antirheumatic drug (bDMARD) and response to methotrexate and was associated with severe disease course in terms of sacroiliitis.
Major finding: The risk for discontinuation of the first bDMARD (hazard ratio [HR] 2.129; P = .011) and methotrexate discontinuation because of therapy failure (HR 2.168; P = .002) were significantly higher among patients with 25(OH)D level of ≤20 vs 20-30 and ≥30 ng/mL, with the prevalence of sacroiliitis being significantly higher in patients with 25(OH)D level of ≤20 vs ≥30 ng/mL (P = .0001).
Study details: Findings are from a retrospective study including 233 patients with PsA.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Rotondo C et al. Vitamin D status and psoriatic arthritis: Association with the risk for sacroiliitis and influence on the retention rate of methotrexate monotherapy and first biological drug survival—A retrospective study. Int J Mol Sci. 2023;24(6):5368 (Mar 10). Doi: 10.3390/ijms24065368